Cargando…

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against programmed death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA-4). In spite of these improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genova, Carlo, Dellepiane, Chiara, Carrega, Paolo, Sommariva, Sara, Ferlazzo, Guido, Pronzato, Paolo, Gangemi, Rosaria, Filaci, Gilberto, Coco, Simona, Croce, Michela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777268/ https://www.ncbi.nlm.nih.gov/pubmed/35069581 http://dx.doi.org/10.3389/fimmu.2021.799455

Ejemplares similares

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
por: Grottoli, Melania, et al.
Publicado: (2022)

Natural killer cell distribution and trafficking in human tissues
por: Carrega, Paolo, et al.
Publicado: (2012)

Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies
por: Carrega, Paolo, et al.
Publicado: (2017)

CTLA-4 checkpoint blockade in breast cancer, a case in point report
por: Dellepiane, Chiara, et al.
Publicado: (2015)

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma
por: Marseglia, Mariarosaria, et al.
Publicado: (2021)

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Genova, Carlo, et al.
Publicado: (2023)

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Cusato, Jessica, et al.
Publicado: (2019)

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma
por: Amaro, Adriana Agnese, et al.
Publicado: (2023)

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
por: Rossi, Giovanni, et al.
Publicado: (2020)

Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition
por: Amaro, Adriana, et al.
Publicado: (2020)

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma
por: Carbone, Antonino, et al.
Publicado: (2023)

Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review
por: Spagnolo, Francesco, et al.
Publicado: (2021)

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients
por: Marconi, Silvia, et al.
Publicado: (2022)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)

Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues
por: Castriconi, Roberta, et al.
Publicado: (2018)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

HLA-C*17 in COVID-19 patients: Hints for associations with severe clinical outcome and cardiovascular risk
por: Bonaccorsi, Irene, et al.
Publicado: (2021)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: Harber, James, et al.
Publicado: (2021)

Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade
por: Fang, Tianxu, et al.
Publicado: (2023)

Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
por: Croce, Michela, et al.
Publicado: (2019)

Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells
por: Carrega, Paolo, et al.
Publicado: (2009)

Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV
por: Filaci, Gilberto, et al.
Publicado: (2018)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
por: Sun, Lu, et al.
Publicado: (2023)

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment
por: Luo, Hong, et al.
Publicado: (2023)

Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
por: Jia, Yunlong, et al.
Publicado: (2020)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
por: Li, Jun-Yan, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy
por: Subramanian, Madhav, et al.
Publicado: (2023)

Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023)

Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment
por: Zhang, Chunlan, et al.
Publicado: (2023)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
por: Jelinic, Petar, et al.
Publicado: (2018)

Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
por: Lee, Yu-Hung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3dncv2q4h847bue0kjhm230tt3